Rashmi Kumar, MD
Gastroenterology · Irvine, CANPI 1396007068
Payments from drug & device makers
Across 298 payments — averaging $533.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$84K
- Johnson & Johnson$71K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$420
- Lilly USA, LLC$252
- Bristol Myers Squibb$165
- plus $615 from 15 others
What the payments were for
- Speaking & faculty fees$67,61643%
- Grants$80,00050%
- Travel & lodging$4,2223%
- Food & beverage$6,8234%
- Education$2260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 36 | $83,957 |
| Johnson & Johnson | 93 | $71,012 |
| AbbVie(2 entities) | 100 | $2,466 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $420 |
| Lilly USA, LLC | 10 | $252 |
| Bristol Myers Squibb | 10 | $165 |
| Sanofi | 5 | $140 |
| Celltrion USA Inc. | 5 | $133 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Boston Scientific | 2 | $42 |
| Braintree Laboratories, Inc. | 2 | $35 |
| Fresenius Kabi USA, LLC | 1 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Merck | 2 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Shionogi Inc | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Dynavax Technologies Corporation | 2 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$158,887 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 28 | $16,484 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 21 | $1,163 |
| Pantoprazole Sodium | 19 | $233 |
| Omeprazole | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Irvine
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
- Gregory WienerChula Vista$3.5M
- Gil MelmedLos Angeles$3M
- Christopher BowlusSacramento$3M
- Bennett RothLos Angeles$2.8M
- Brigid BolandSan Diego$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.